{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:02:05Z","timestamp":1792116125279,"version":"4.4.0"},"reference-count":195,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved\u2014daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and other metabolites.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Among the various mechanisms by which CD38 antibodies can induce MM cell death is immunomodulation, including multiple pathways for CD38\u2010mediated T\u2010cell activation. Patients who respond to anti\u2010CD38 targeting treatment experience more marked changes in T\u2010cell expansion, activity, and clonality than nonresponders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications<\/jats:title><jats:p>Resistance mechanisms that undermine the immunomodulatory effects of CD38\u2010targeting therapies can be tumor intrinsic, such as the downregulation of CD38 surface expression and expression of complement inhibitor proteins, and immune microenvironment\u2010related, such as changes to the natural killer (NK) cell numbers and function in the bone marrow niche. There are numerous strategies to overcome this resistance, which include identifying and targeting other therapeutic targets involved in, for example, adenosine production, the activation of NK cells or monocytes through immunomodulatory drugs and their combination with elotuzumab, or with bispecific T\u2010cell engagers.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6619","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:40:54Z","timestamp":1697438454000},"page":"20332-20352","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Immunomodulatory properties of <scp>CD38<\/scp> antibodies and their effect on anticancer efficacy in multiple myeloma"],"prefix":"10.1002","volume":"12","author":[{"given":"Kamlesh","family":"Bisht","sequence":"first","affiliation":[{"name":"Sanofi Oncology  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Fukao","sequence":"additional","affiliation":[{"name":"Sanofi Oncology  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Chiron","sequence":"additional","affiliation":[{"name":"Sanofi Research &amp; Development  Vitry\u2010sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center Dana Farber Cancer Institute, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[{"name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center  Baltimore Maryland USA"},{"name":"Department of Medicine University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Chini","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore National University of Singapore  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"Van\u00a0De\u00a0Velde","sequence":"additional","affiliation":[{"name":"Sanofi Oncology  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Malavasi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences University of Turin  Torino Italy"},{"name":"Fondazione Ricerca Molinette  Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,15]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Cancer Stat Facts: Myeloma.National Cancer Institute. Accessed July 17 2023.https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2308.bloodjournal8762308"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091261"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14241"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30249-2"},{"key":"e_1_2_11_9_1","unstructured":"First\u2010in\u2010human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma.ClinicalTrials.gov. September 14 2022. Accessed July 17 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04000282"},{"key":"e_1_2_11_10_1","unstructured":"CID\u2010103 (Anti\u2010CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma.ClinicalTrials.gov. April 22 2022. Accessed July 17 2023.https:\/\/clinicaltrials.gov\/study\/NCT04758767"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01395-0"},{"key":"e_1_2_11_12_1","unstructured":"Janssen.DARZALEX Prescribing Information.2022."},{"key":"e_1_2_11_13_1","unstructured":"Janssen.DARZALEX SmPC.2022."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_2_11_16_1","unstructured":"European Medicines Agency.Sarclisa. Accessed July 17 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries\u2010opinion\/sarclisa\u20100"},{"key":"e_1_2_11_17_1","unstructured":"Sanofi\u2010Aventis U.S. LLC.Sarclisa\u00ae (isatuximab\u2010irfc) [package insert].2021. Accessed July 17 2023.https:\/\/products.sanofi.us\/Sarclisa\/Sarclisa.pdf"},{"key":"e_1_2_11_18_1","unstructured":"Sanofi Co. Ltd.Sarclisa\u00ae (isatuximab) [package insert].2021. Accessed July 17 2023.https:\/\/products.sanofi.us\/Sarclisa\/Sarclisa.pdf"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012448"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1007783"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01020-y"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.01.009"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.02.011"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02052-6"},{"key":"e_1_2_11_26_1","unstructured":"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic Non\u2010Small Cell Lung or Triple Negative Breast Cancers That Have Advanced or Have Spread. ClinicalTrials.gov. July 23 2021. Accessed July 17 2023.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03098550"},{"key":"e_1_2_11_27_1","unstructured":"Daratumumab or FMS Inhibitor JNJ\u201040346527 Before Surgery in Treating Patients With High\u2010Risk Resectable Localized or Locally Advanced Prostate Cancer. ClinicalTrials.gov. February 28 2022. Accessed July 17 2023.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03177460"},{"issue":"2","key":"e_1_2_11_28_1","article-title":"Daratumumab plus atezolizumab in previously treated advanced or metastatic NSCLC: brief report on a randomized, open\u2010label, phase 1b\/2 study (LUC2001 JNJ\u201054767414)","volume":"2","author":"Pillai RN","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003697"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100562"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2130751"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00760"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0587-5"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.TUMIMM16-B26"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-8749(03)00025-X"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324728"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2490"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.4.397"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.1.395"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174169"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2021.102514"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2002700"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003996"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.02.001"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161209787185788"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.03.007"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2016.00198"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells4030520"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00305"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004332"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-740944"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1039\/D1RA06266B"},{"issue":"9","key":"e_1_2_11_57_1","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein AL","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"8","key":"e_1_2_11_58_1","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non\u2010canonical adenosinergic pathways and produce adenosine from ATP and NAD+","volume":"7","author":"Morandi F","year":"2018","journal-title":"Onco Targets Ther"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17329"},{"issue":"2","key":"e_1_2_11_60_1","first-page":"30","article-title":"Papel Dd Las Ves\u00edculas Extracelulares En La Resistencia Al Anticuerpo Monoclonal Anti\u2010CD38 Isatuximab En Mieloma M\u00faltiple","volume":"41","author":"Gonz\u00e1lez Rodr\u00edguez M","year":"2022","journal-title":"Sangre"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.160"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2348.2348"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.122"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074617"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215337"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00060"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.24"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1596"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.259796.115"},{"issue":"6","key":"e_1_2_11_70_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0233-3","article-title":"Hypoxia and aging","volume":"51","author":"Yeo EJ","year":"2019","journal-title":"Exp Mol Med"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00635-3"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2826"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02533"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605251103"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00109"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203373"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.002"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-640532"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04917-5"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268656"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.68148"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129456"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006200"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008209"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002123"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115566"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0260"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.240"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26154658"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-5468"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071716"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0855-4"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16548"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1632"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-4209"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0536-3"},{"key":"e_1_2_11_107_1","unstructured":"BeksacM RichardsonP UnalA et\u00a0al.2289 Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma and Soft\u2010Tissue Plasmacytomas: Icaria\u2010MM Subgroup Analysis. 62nd ASH Annual Meeting and Exposition; 2020; Virtual."},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01343-w"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147897"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.013"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.47"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13835"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17499"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1983427"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168685"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280660"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169533"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16292"},{"key":"e_1_2_11_132_1","doi-asserted-by":"crossref","unstructured":"Philippe MoreauTF UsmaniS BahlisNJ et\u00a0al.3245 Daratumumab Plus Lenalidomide and Dexamethasone (D\u2010Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant\u2010Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study. American Society of Hematology; December 11 2022; New Orleans LA.","DOI":"10.1182\/blood-2022-163494"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162339"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14018"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04978-6"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05188-4"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020256"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117441"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01228"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00930-19"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2027"},{"key":"e_1_2_11_142_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3935.3935"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01197-w"},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014485"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.779"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12561"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31430-0"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169943"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164901"},{"key":"e_1_2_11_150_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00293"},{"key":"e_1_2_11_151_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.816499"},{"key":"e_1_2_11_152_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1994.tb00414.x"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.3390\/hemato2020010"},{"issue":"5","key":"e_1_2_11_154_1","article-title":"NK cell phenotype is associated with response and resistance to Daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij CPM","year":"2023","journal-title":"Hema"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164812"},{"key":"e_1_2_11_156_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0810-4"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.778409"},{"key":"e_1_2_11_158_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201141894"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25020367"},{"key":"e_1_2_11_160_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159137"},{"key":"e_1_2_11_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.08.014"},{"key":"e_1_2_11_162_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010167"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8588"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1813"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.5712.5712"},{"key":"e_1_2_11_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.123"},{"key":"e_1_2_11_167_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.4018.4018"},{"key":"e_1_2_11_168_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1610-3"},{"key":"e_1_2_11_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164656"},{"key":"e_1_2_11_170_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.42"},{"issue":"10","key":"e_1_2_11_171_1","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose J","year":"2018","journal-title":"Onco Targets Ther"},{"key":"e_1_2_11_172_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000610"},{"key":"e_1_2_11_173_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0018"},{"key":"e_1_2_11_174_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148174"},{"key":"e_1_2_11_175_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168275"},{"key":"e_1_2_11_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.04.091"},{"key":"e_1_2_11_177_1","unstructured":"IPH5201 as Monotherapy or in Combination with Durvalumab +\/\u2212 Oleclumab in Subjects with Advanced Solid Tumors. ClinicalTrials.gov. August 15 2022. Accessed July 17 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261075"},{"key":"e_1_2_11_178_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004089"},{"key":"e_1_2_11_179_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00930-1"},{"key":"e_1_2_11_180_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305"},{"key":"e_1_2_11_181_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227579"},{"key":"e_1_2_11_182_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141"},{"key":"e_1_2_11_183_1","unstructured":"Phase 1\/2 Study of ISB 1442 in Relapsed\/Refractory Multiple Myeloma. ClinicalTrials.Gov. October 17 2022. Accessed July 17 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05427812"},{"key":"e_1_2_11_184_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005220"},{"key":"e_1_2_11_185_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122853"},{"key":"e_1_2_11_186_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_187_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_11_188_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148723"},{"key":"e_1_2_11_189_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8003"},{"issue":"3","key":"e_1_2_11_190_1","first-page":"260","article-title":"Pre\u2010clinical characterization of ISB 1342, a CD38xCD3 T\u2010cell engager for relapsed\/refractory multiple myeloma","volume":"142","author":"Pouleau B","year":"2023","journal-title":"Blood"},{"key":"e_1_2_11_191_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00294-9"},{"key":"e_1_2_11_192_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0004-z"},{"key":"e_1_2_11_193_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169072"},{"key":"e_1_2_11_194_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157547"},{"key":"e_1_2_11_195_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8039"},{"key":"e_1_2_11_196_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:19:32Z","timestamp":1741749572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":195,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/cam4.6619"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6619","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}